Found 201 clinical trials
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Niraparib works by blocking a substance produced by the body (PARP enzymes) in a way that tumor cells can be killed, or made more susceptible to chemotherapy.
- 0 views
- 19 Feb, 2024
- 4 locations
Azacitidine Venetoclax and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
This phase II trial investigates how well azacitidine, venetoclax, and trametinib work in treating patients with acute myeloid leukemia or higher-risk myelodysplastic syndrome that has come back (relapsed) or has not responded to treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer …
- 0 views
- 19 Feb, 2024
- 1 location
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)
These regional therapies mainly aim to achieve a delay of further progression of the prostate cancer disease, and thus delay the initiation of palliative, sustained drug therapy. Previous standard or common practice at salvage lymph node dissection is the removal on both sides of the pelvic lymph nodes even if …
- 0 views
- 19 Feb, 2024
- 1 location
A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)
This study is a randomized, national multicenter clinical study which is designed to compare the efficacy of the safety and efficacy of treatment every 3 weeks or 6 weeks in (Non-small-cell-cell cancer, NSCLC) subjects without systematic treatment who used Pembrolizumab after 6 cycles of combined chemotherapy estimated with stable efficacy …
- 0 views
- 19 Feb, 2024
- 1 location
Cryoablation Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing …
- 0 views
- 19 Feb, 2024
- 1 location
Neo-TACE-HAIC for BCLC B Stage HCC (Neoconcept)
Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for unresectable HCC. Pilot study showed TACE combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate.
- 0 views
- 19 Feb, 2024
- 1 location
Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments
Current treatments imply cervical conisation or hysterectomy, with or without lymphadenectomy and or radiotherapy, or chemotherapy. However, few pharmacological options are available against oncogenic papilloma viruses and thus against recurrences The aim of this project is to develop relevant organoids models from patient biopsies that will be used to identify …
- 0 views
- 19 Feb, 2024
- 1 location
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Adults who have been diagnosed with B-cell non-Hodgkin lymphoma (NHL) that has relapsed or no longer responds to chemotherapy (relapsed or refractory) may be eligible to participate in this study. The investigators will use participants own immune cells, called T cells, to kill the lymphoma.
- 0 views
- 19 Feb, 2024
- 1 location
Neoadjuvant mFOLFOXIRI Plus Bevacizumab With Selective Radiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer
A small single-center phase II pilot trial treated patients with stage II or III rectal cancer with induction FOLFOX/bevacizumab chemotherapy followed by CRT only in those with stable or progressive disease and resection in all patients. All 32 of the participants had an R0 resection, and the 4-year DFS was …
- 0 views
- 19 Feb, 2024
- 1 location
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
This is an open-label, non-randomised, phase II, exploratory, multi-country and multi-centre clinical trial. Chemotherapy-nave patients with EML4-ALK rearrangement and with locally advanced or metastatic non-small cell lung cancer patients will be selected.
- 0 views
- 19 Feb, 2024
- 15 locations